253 related articles for article (PubMed ID: 29149832)
1. Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks.
Petanidis S; Kioseoglou E; Salifoglou A
Curr Med Chem; 2019; 26(4):607-623. PubMed ID: 29149832
[TBL] [Abstract][Full Text] [Related]
2. Copper, gold and silver compounds as potential new anti-tumor metallodrugs.
Tan SJ; Yan YK; Lee PP; Lim KH
Future Med Chem; 2010 Oct; 2(10):1591-608. PubMed ID: 21426151
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
4. Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties.
Kiss T; Enyedy ÉA; Jakusch T; Dömötör O
Curr Med Chem; 2019; 26(4):580-606. PubMed ID: 29521198
[TBL] [Abstract][Full Text] [Related]
5. Mitochondria-Targeting Anticancer Metal Complexes.
Erxleben A
Curr Med Chem; 2019; 26(4):694-728. PubMed ID: 29521200
[TBL] [Abstract][Full Text] [Related]
6. Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: Mechanism-driven new therapy development.
Wang H; Zhou Y; Xu X; Li H; Sun H
Curr Opin Chem Biol; 2020 Apr; 55():171-179. PubMed ID: 32200302
[TBL] [Abstract][Full Text] [Related]
7. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy.
Liu J; Lai H; Xiong Z; Chen B; Chen T
Chem Commun (Camb); 2019 Aug; 55(67):9904-9914. PubMed ID: 31360938
[TBL] [Abstract][Full Text] [Related]
8. Novel metals and metal complexes as platforms for cancer therapy.
Frezza M; Hindo S; Chen D; Davenport A; Schmitt S; Tomco D; Dou QP
Curr Pharm Des; 2010 Jun; 16(16):1813-25. PubMed ID: 20337575
[TBL] [Abstract][Full Text] [Related]
9. Novel metal-based anticancer drugs: a new challenge in drug delivery.
Lainé AL; Passirani C
Curr Opin Pharmacol; 2012 Aug; 12(4):420-6. PubMed ID: 22609113
[TBL] [Abstract][Full Text] [Related]
10. Metallodrugs: an approach against invasion and metastasis in cancer treatment.
González-Ballesteros MM; Mejía C; Ruiz-Azuara L
FEBS Open Bio; 2022 May; 12(5):880-899. PubMed ID: 35170871
[TBL] [Abstract][Full Text] [Related]
11. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.
van Rijt SH; Sadler PJ
Drug Discov Today; 2009 Dec; 14(23-24):1089-97. PubMed ID: 19782150
[TBL] [Abstract][Full Text] [Related]
12. Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy.
Hecel A; Kolkowska P; Krzywoszynska K; Szebesczyk A; Rowinska-Zyrek M; Kozlowski H
Curr Med Chem; 2019; 26(4):624-647. PubMed ID: 28933286
[TBL] [Abstract][Full Text] [Related]
13. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
[TBL] [Abstract][Full Text] [Related]
14. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
15. Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.
Leon IE; Cadavid-Vargas JF; Di Virgilio AL; Etcheverry SB
Curr Med Chem; 2017; 24(2):112-148. PubMed ID: 27554807
[TBL] [Abstract][Full Text] [Related]
16. From metallodrugs to metallodendrimers for nanotherapy in oncology: a concise overview.
El Kazzouli S; El Brahmi N; Mignani S; Bousmina M; Zablocka M; Majoral JP
Curr Med Chem; 2012; 19(29):4995-5010. PubMed ID: 22963626
[TBL] [Abstract][Full Text] [Related]
17. Metal/N-heterocyclic carbene complexes: opportunities for the development of anticancer metallodrugs.
Cisnetti F; Gautier A
Angew Chem Int Ed Engl; 2013 Nov; 52(46):11976-8. PubMed ID: 24115500
[No Abstract] [Full Text] [Related]
18. All-atom simulations to studying metallodrugs/target interactions.
Janoš P; Spinello A; Magistrato A
Curr Opin Chem Biol; 2021 Apr; 61():1-8. PubMed ID: 32781390
[TBL] [Abstract][Full Text] [Related]
19. Metal Drugs and the Anticancer Immune Response.
Englinger B; Pirker C; Heffeter P; Terenzi A; Kowol CR; Keppler BK; Berger W
Chem Rev; 2019 Jan; 119(2):1519-1624. PubMed ID: 30489072
[TBL] [Abstract][Full Text] [Related]
20. Overview.
Prudhomme M
Anticancer Agents Med Chem; 2017; 17(1):2. PubMed ID: 28143383
[No Abstract] [Full Text] [Related]
[Next] [New Search]
